SPARC在其实验药物在psoralpic和皮肤炎试验中失败后,其股份暴跌。 SPARC's shares plummet after its experimental drug fails in psoriasis and dermatitis trials.

SPARC是太阳制药公司的一个研究部门,在SCD-044实验药物SCD-044未能达到治疗psoralpic和外皮皮炎的临床试验目标之后,SPARC的股份下降了18%以上。 Shares of SPARC, a research arm of Sun Pharmaceutical, dropped over 18% after its experimental drug SCD-044 failed to meet clinical trial goals for treating psoriasis and atopic dermatitis. 该药物在这两种情况的严重程度指数方面没有达到所要求的改进。 The drug did not achieve the required improvements in severity indices for both conditions. 尽管收入总额最近有所增加,但SPARC的利润率下降,由于停用该药物,其份额目前前景黯淡。 Despite a recent increase in total income, SPARC's profitability declined, and its shares are now in a bearish outlook due to the drug's discontinuation.